Finanzen von MapLight Therapeutics Inc (MPLT)MPLTMapLight Therapeutics Inc

Evaluating the bottom line, MapLight Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -445.24%, provide a clear picture of how effectively MPLT converts its operational activities into shareholder value.

In the context of the broader market, MPLT competes directly with industry leaders such as SGMT and IRWD. With a market capitalization of $544.94M, it holds a significant position in the sector. When comparing efficiency, MPLT's gross margin of N/A stands against SGMT's N/A and IRWD's 100.00%. Such benchmarking helps identify whether MapLight Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

MapLight has reported negative net income for several quarters, with the latest figures showing a net income of -60,668,000 USD for Q1 2026 and -60,192,000 USD for Q2 2026. The forward P/E ratio is currently at 0, indicating a lack of earnings expectations.